Rhythm Pharmaceuticals, Inc.
RYTMHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. With a market capitalization of $7.07B, it sits in mid-cap territory. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Market Cap
$7.07B
Beta
1.97
P/E (TTM)
—
P/E (Fwd)
-167.26
EPS (TTM)
$-3.12
EPS (Fwd)
$-0.61
ROE
-117.1%
ROA
-31.0%
Cash
$330.9M
Total Debt
$109.8M
Free CF
-$130.6M
52W Change
1.3%
Annual Financials
Cash vs Debt
Where RYTM stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RYTM finished 8.28% above its 150-day moving average ($97.36) and 5.90% above its 200-day moving average ($99.55). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RYTM overbought or oversold?
At the September 3, 2026 close, RYTM's RSI(14) was 27.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $330.9M in cash and $109.8M in debt, RYTM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$130.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -117.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $23.6M (2022) to $189.8M (2025), reflecting a 703% increase over the period.
Rhythm Pharmaceuticals, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RYTM.